Recent Insider Trading: HCP, Inc.

HCP, Inc. (NYSE:HCP) insider has recently participated in insider trading activity. Executive Vice President, Kirby Thomas D bought 500 shares for $13,051 via one transaction Feb 12. Another notable insider trading was done by McHenry Troy E. on Feb 11, who is the EVP, Gen Counsel and Corp Sec. The insider acquired 1,000 shares at an average price of $25.74. Moreover, an insider buying of 3,822 shares was carried out by Kowalske Darren A, Executive Vice President, on Feb 11. Following the transaction, the insider now owns 3,822 shares in total. Executive Vice President Lu Lihpang bought 200 shares for $5,201 through one transaction Feb 11. Following this sale, this insider’s stake in the company comprises 29,790 shares, priced at $801648.9 as of Tuesday.

The stock has experienced a total of 61 insider trades in the past three months. These trades include 42 sell activities and 19 buy trades. Furthermore, over the past 12 months, the stock was traded 90 times by insiders. In 57 of these trades, the insider was a seller while an employee of the company was the buyer in just 33 instances.

HCP, Inc. (HCP) on February 9, 2016 announced results for the quarter and year ended December 31, 2015.

FOURTH QUARTER 2015 AND RECENT HIGHLIGHTS

—    FFO as adjusted and FAD per share increased year-over-year by 1% to $0.80 and 2% to $0.67, respectively; FFO per share and EPS were ($0.99) and ($1.29), respectively

—    Raised $1.1 billion from capital recycling and financing activities, including $600 million of 4.0% senior unsecured notes that paid down 36% of 2016 debt maturities

—    Completed $208 million of investment transactions

—    Leased 911,000 sq. ft. in our life science and medical office portfolios, bringing occupancy to 98.2% and 91.9%, respectively

FULL YEAR 2015 HIGHLIGHTS

—    FFO as adjusted and FAD per share increased year-over-year by 4% to $3.16 and 6% to $2.72, respectively; FFO per share and EPS were ($0.02) and ($1.21), respectively

—    Completed $2.1 billion of accretive investments, including:

—    $1.1 billion in private pay senior housing, led by the $847 million acquisition of Chartwell’s portfolio

—    $700 million expansion in our life science and MOB office platform, including a new $225 million institutional joint venture with Morgan Stanley owning an on-campus MOB portfolio, and $177 million Class A life science development of The Cove Phase I

—    $278 million increase in our international investments, expanding our U.K. care home portfolio

—    Raised $3 billion from financing and capital recycling activities, including $2.3 billion of debt at a blended rate of 3.5%

—    Selling 50 HCR ManorCare non-strategic assets with expected proceeds of $350 million (80% received to date)